Arifulla Khan1, Sarah Atkinson1, Irina Mezhebovsky1, Fahua She1, Todd Leathers1, Sanjeev Pathak1. 1. Dr. Khan, MD, Northwest Clinical Research Center, Bellevue, WA; Duke University School of Medicine, Department of Psychiatry and Behavioral Sciences, Durham, NC. Dr. Atkinson, MD, Finger Lakes Clinical Research, Rochester, NY. Dr. Mezhebovsky, MD, Boston Clinical Trials Inc, Boston, MA. Drs. She, MD and Pathak, MD and Mr Leathers, MBA, AstraZeneca Pharmaceuticals, Wilmington, DE, USA.
Abstract
OBJECTIVE: To evaluate the efficacy and tolerability of adjunct extended release quetiapine fumarate (quetiapine XR) in patients with generalized anxiety disorder (GAD) and inadequate response to selective serotonin reuptake inhibitors/ serotonin norepinephrine reuptake inhibitors (SSRI/SNRIs). METHODS: 11-week (1-week single-blind placebo run-in; 8-week randomized treatment; 2-week post-treatment period), double-blind, placebo-controlled study. Patients were randomized to quetiapine XR or placebo adjunct to SSRI/SNRI. 50 mg initial dose; 150 mg/day, Day 3; 300 mg/day, Weeks × and 4 if indicated (Clinical Global Impressions-Severity of Illness [CGI-S] ≥ 4; 150 mg/day tolerated). Primary endpoint: change from randomization to Week 8 in HAM-A total score. Secondary variables: Hamilton Rating Scale for Anxiety (HAM-A) psychic/somatic clusters, response and remission; and CGI-S. RESULTS:409 patients were randomized to quetiapine XR (n = 209) or placebo (n = 200); 41% and 55% of patients, respectively, had dose increases (300 mg/day). Week 8 mean change in HAM-A total score was not statistically significant for quetiapine XR (-10.74; p = 0.079) versus placebo (-9.61). Secondary variables were generally consistent with the primary analysis, except a significant reduction in HAM-A total score at Week 1 (-6.45, quetiapine XR versus -4.47, placebo; p < 0.001); significant improvements in HAM-A psychic cluster (p < 0.05) and CGI-S total (p < 0.05) scores at Week 8. Adverse events (.10% either group) were dry mouth, somnolence, sedation, headache, and dizziness. CONCLUSIONS: In patients with GAD and inadequate response to SSRI/SNRI, adjunct quetiapine XR did not show a statistically significant effect for the primary endpoint at Week 8, although some secondary endpoints were statistically significant versus placebo. Quetiapine XR was generally well tolerated.
RCT Entities:
OBJECTIVE: To evaluate the efficacy and tolerability of adjunct extended release quetiapine fumarate (quetiapine XR) in patients with generalized anxiety disorder (GAD) and inadequate response to selective serotonin reuptake inhibitors/ serotonin norepinephrine reuptake inhibitors (SSRI/SNRIs). METHODS: 11-week (1-week single-blind placebo run-in; 8-week randomized treatment; 2-week post-treatment period), double-blind, placebo-controlled study. Patients were randomized to quetiapine XR or placebo adjunct to SSRI/SNRI. 50 mg initial dose; 150 mg/day, Day 3; 300 mg/day, Weeks × and 4 if indicated (Clinical Global Impressions-Severity of Illness [CGI-S] ≥ 4; 150 mg/day tolerated). Primary endpoint: change from randomization to Week 8 in HAM-A total score. Secondary variables: Hamilton Rating Scale for Anxiety (HAM-A) psychic/somatic clusters, response and remission; and CGI-S. RESULTS: 409 patients were randomized to quetiapine XR (n = 209) or placebo (n = 200); 41% and 55% of patients, respectively, had dose increases (300 mg/day). Week 8 mean change in HAM-A total score was not statistically significant for quetiapine XR (-10.74; p = 0.079) versus placebo (-9.61). Secondary variables were generally consistent with the primary analysis, except a significant reduction in HAM-A total score at Week 1 (-6.45, quetiapine XR versus -4.47, placebo; p < 0.001); significant improvements in HAM-A psychic cluster (p < 0.05) and CGI-S total (p < 0.05) scores at Week 8. Adverse events (.10% either group) were dry mouth, somnolence, sedation, headache, and dizziness. CONCLUSIONS: In patients with GAD and inadequate response to SSRI/SNRI, adjunct quetiapine XR did not show a statistically significant effect for the primary endpoint at Week 8, although some secondary endpoints were statistically significant versus placebo. Quetiapine XR was generally well tolerated.
Authors: Nizar El-Khalili; Mark Joyce; Sarah Atkinson; Robert J Buynak; Catherine Datto; Petter Lindgren; Hans Eriksson Journal: Int J Neuropsychopharmacol Date: 2010-02-23 Impact factor: 5.176
Authors: Martin A Katzman; Olga Brawman-Mintzer; Efren B Reyes; Bengt Olausson; Sherry Liu; Hans Eriksson Journal: Int Clin Psychopharmacol Date: 2011-01 Impact factor: 1.659
Authors: Martin M Katz; Uriel M Halbreich; Charles L Bowden; Alan Frazer; Roger M Pinder; A John Rush; David P Wheatley; Barry D Lebowitz Journal: Neuropsychopharmacology Date: 2002-09 Impact factor: 7.853
Authors: Andrew J Cutler; Stuart A Montgomery; David Feifel; Arthur Lazarus; Mikael Aström; Martin Brecher Journal: J Clin Psychiatry Date: 2009-04-07 Impact factor: 4.384
Authors: Michael Bauer; Herman W Pretorius; Eric L Constant; Willie R Earley; Johan Szamosi; Martin Brecher Journal: J Clin Psychiatry Date: 2009-04-07 Impact factor: 4.384
Authors: René S Kahn; S Charles Schulz; Veselin D Palazov; Efren B Reyes; Martin Brecher; Ola Svensson; Henrik M Andersson; Didier Meulien Journal: J Clin Psychiatry Date: 2007-06 Impact factor: 4.384